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Amaç: Kronik hepatit B tedavisine başlama kararını vermede 
karaciğer biyopsisi önemli bir mihenk taşıdır. Uygun zamanı 
belirlemek için viral yük ve karaciğer fonksiyon testleri ile takip 
yapılmaktadır. Bu çalışmada hepatit B e antigen (HBeAg) negatif 
kronik hepatit B hastalarında karaciğer fibrozisini etkileyen faktörler 
araştırıldı. 
Gereç ve Yöntemler: Karaciğer biyopsisi ve alanin aminotransferaz 
(ALT), aspartat aminotransferaz (AST), gama-glutamil transpeptidaz 
(GGT) ve hepatit B virüs (HBV)-DNA gibi laboratuvar testleri geriye 
dönük olarak hasta dosyalarından toplandı. Çalışma protokolüne 
göre nekroenflamatuvar skor ≤4 ve fibrozis skoru ≤1 tespit edilenler 
normal karaciğer (NK), bu skorlardan birindeki yüksek değer kronik 
hepatit (KH) olarak kabul edildi.
Bulgular: Çalışmaya toplam 234 hastanın karaciğer biyopsisi dahil 
edildi. Toplam 74 (%31,6) hastanın biyopsi sonucu NK olarak kabul 
edildi. Tek değişkenli analizlerde yaş, cinsiyet, ALT, AST, GGT, AFP ve 
HBV-DNA >100,000 IU/mL düzeyi NK ve KH arasında istatistiksel 
olarak farklıydı. Çok değişkenli analizlerde ise yaş, AST >29 U/L ve 
AFP >2,5 ng/mL düzeyi KH için bağımsız risk faktörüydü.
Sonuç: Sonuçlarımıza göre, yaş, AST ve AFP, KH’yi öngörmektedir. 
Kronik hepatit B hastalarını izleyen doktorlar, karaciğer biyopsisi kararı 
alırken bu parametreleri dikkatli bir şekilde değerlendirmelidir. 
Anahtar Kelimeler: Kronik hepatit B, karaciğer Biyopsisi, Fibrozis
Objectives: Liver biopsy (LB) is an important cornerstone in 
decision to start treatment for chronic hepatitis B (HB). Viral load 
and liver function tests are performed to determine the most 
appropriate time. In this study, factors affecting liver fibrosis in 
hepatitis B e antigen (HBeAg) negative chronic hepatitis B patients 
were investigated.
Materials and Methods: LB and the other laboratory results such as 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
gamma-glutamyl transpeptidase (GGT), and hepatitis B virus (HBV)-
DNA were collected from patient files, retrospectively. According to 
study protocol, necroinflammatory scores ≤4 and fibrosis scores ≤1 
were accepted as normal liver (NL), and the high value in one of 
these scores was accepted as chronic hepatitis (CH).
Results: A total of 234 patient’s LBs included in the study. A total of 
74 (31.6%) patients’ LB was evaluated as NL. In univariate analysis, 
age, gender, ALT, AST, GGT, AFP and HBV-DNA >100.000 IU/mL, 
and in multivariate analysis, age, AST level >29 U/L, and AFP level 
>2.5 ng/mL were the independent risk factors for CH.
Conclusion: According to our results, age, AST and AFP predict 
CH. Doctors who follow up chronic hepatitis B patients should be 
carefully evaluate these parameters when giving LB decision.
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Introduction
Hepatitis B virus (HBV) infect the liver and can lead to a broad 
spectrum of disease, ranging from an inactive carriage to cirrhosis 
and hepatocellular carcinoma (HCC) (1). The overall hepatitis B 
surface antigen (hBsAg) seropositivity in Turkey was 4% (2.3% in 
the western and 7.3% in the eastern regains (2).
Chronic hepatitis B (CHB) may present either as hepatitis B 
e antigen (HBeAg)-positive or HBeAg-negative. HBeAg-negative 
form of the disease has been increasing. In Turkey, HBeAg-negative 
form is the most prevalant form (90%) (3). European Association 
for the Study of the Liver guidelines recommended antiviral therapy 
for HBeAg-negative CHB patients if their liver biopsy showing 
at least moderate necroinflammation and/or at least moderate 
fibrosis when their alanine aminotransferase (ALT) level higher 
than the upper limit of normal (ULN) and HBV-DNA levels above 
2.000 IU/mL. Patients with HBV-DNA >20.000 IU/mL and ALT >2 
x ULN can start treatment even without a liver biopsy (1). However, 
approximately one third of patients who have persistently normal 
ALT levels have moderate inflammation and/or advanced fibrosis, 
particularly patients older than 35 years old (4,5).  So, the sufficiency 
of monitoring HBeAg-negative patients with ALT is controversial. 
Liver biopsy is often recommended for determining the degree 
of necroinflammation and fibrosis since hepatic histology can 
asist the decision to start treatment (6). In this study, we aimed to 
investigate factors that affect the degree of necroinflammation and 
fibrosis in liver biopsiy, in HBeAg-negative CHB patients.
Matherials and Methods
This study was conducted in a tertiary care hospital. Liver 
biopsy results between 2009 and 2013 were collected from patient 
files retrospectively. Demographic characteristics and laboratory 
parameters which were made with in one year before liver biopsy 
were obtained from the patients’ files, too.
Inclusion criteria for patients;
- Being HBsAg-positive for at least six months,
- Being HBeAg-negative and anti-HBe positive,
- Being older than 18 years,
- Antiviral and interferon therapy naive patients.
Exclusion Criteria for Patients
- Coinfection with hepatitis C virus, hepatitis D virus or human 
immunodeficiency virus,
- A co-existing disease (Wilson disease, hemochromatosis, 
autoimmune disease, HCC or other malignant diseases
- A history of using systemic corticosteroid, antineoplastic or 
immunomodulator drugs.
The Biopsy Decision
The indications for liver biopsy are based mainly on the 
combination of three criteria; serum HBV-DNA levels, serum ALT 
levels and age. ULN of ALT was accepted as 35 U/L.
- Liver biopsy was performed in all patients with ALT above 2 
times ULN and serum HBV-DNA above 20.000 IU/mL.
- In patients who have serum HBV-DNA above 2.000IU/mL 
but normal ALT levels, liver biopsy was performed when the 
second HBV-DNA determination was found above 2.000IU/mL 
again during 3-6 months period and the patients’ age was above 
35 years.
Biopsy procedure: Percutaneous liver biopsy was performed 
with tru-cut biopsy method. Disposable 16-18 G semi-automatic 
tru-cut biopsy needles (Geotek Healthcare products, Turkey; Matek 
Medical Inc, Turkey) was used in the biopsies. Obtained specimens 
were sent to pathology laboratory in formalin. Grading and staging 
of histological activity index was scored with the modified Ishac 
score system (7).
Necroinflammatory scores ≤4 and fibrosis scores ≤1 were 
accepted as normal or minimally affected liver (NL) (8). The high 
value in one of these scores was accepted as CH.
The study protocol was approved by the Ethics Committee 
of Sakarya University Faculty of Medicine (approval number: 
2013/71522473.050.01.04/37). This study was carried out in 
accordance with the principles of the Helsinki Declaration).
Statistical Analysis
Kolmogorov-Smirnov test was used to evaluate whether the 
distribution of variables were normal. Therefore, two independent 
Sample t-test was used to compare the normal distributed 
continuous variables between groups. The normal distributed 
continuous variables were presented as the mean ± standard 
deviation. Mann-Whitney U test was used to compare the non-
normal distributed continuous variables between groups. The 
non-normal distributed continuous variables were presented as the 
median and interquartile range (quartile 1 to 3). Categorical variables 
were compared by Pearson’s or Yates corrected chi-square tests. 
Categorical variables were presented as a count and percentage.
Receiver operating characteristic (ROC) curve analysis was 
performed to establish the most accurate diagnostic method 
(biomarker) to discriminate between CH and normal patients. ROC 
curves were constructed for ALT, aspartate aminotransferase (AST), 
gamma-glutamyl transpeptidase (GGT), and alpha-fetoprotein (AFP) 
to test the various biomarkers in predicting CH (Figure 1). The areas 
under the ROC curves (AUC) were calculated and the specificity, 
sensitivity, positive-predictive value, negative-predictive value, 
accuracy, for the ALT, AST, GGT and AFP of the most appropriate 
cut-off point were calculated for predicting CH. A multivariate 
logistic regression model was implemented to determine ALT, AST, 
GGT and AFP and other covariates associated with CH. A p-values 
<0.05 were considered significant. Analyses were performed using 
commercial software (IBM SPSS Statistics 20, SPSS inc., an IBM 
Co., Somers, NY; MedCalc 12.7, MedCalc Software bvba, Ostend, 
Belgium).
Results
In total, 268 liver biopsies were performed during the study 
period. Among these patients, 234 (87.3%) of them were HBeAg 
negative (140 males, 94 females). So, further evaluation was done 
with these patients according to our inclusion criteria. Mean age of 
HBeAg negative patients was 41.5±11.3 years. Mean ALT value 
was 56.9 U/L and 116 (49.6%) of them have ALT in the normal 
range. Of the patients, 142 (60.7%) had HBV-DNA >20.000IU/mL. 
Baseline demographic and other characteristics of patients are 
shown in Table 1.
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Patients’ total necroinflammatory score median was 5 (range: 
1-16) and the fibrosis component was 2 (range: 0-5). Of the total, 
31 (13.2%) patients had no fibrosis, 162 (69.2%) had portal fibrotic 
expansion (stages 1 and 2), 38 (16.2%) had bridging fibrosis (stages 
3 and 4), and 3 (1.3%) had cirrhosis (stage 5). Among 31 patients 
who had no fibrosis, 28 patients had also ≤4 necroinflammatory 
scores, 12 patients had <20.000 IU/mL HBV-DNA, and 20 patients 
had normal ALT levels.
A total of 74 (31.6 %) patients’ liver biopsy was evaluated as in 
normal or minimally affected liver. In univariate analysis, all baseline 
characteristics except mean HBV-DNA value were statistically 
different between NL and CH (Table 2). When patients analyzed by 
grouping with HBV-DNA level, meaningful statistical difference was 
observed between NL and CH if the cut off value was accepted as 
100.000 IU/mL (p=0.04) or 1.000.000 IU/mL (p=0.005). Statistical 
difference was not found when the cut off value of HBV-DNA was 
accepted as <20.000 IU/mL (p=0.65) (Table 2).
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HBV-DNA IU/mL 33682 (7756.5-939050.5)
Log (HBV-DNA) IU/mL 4.53 (3.89-5.97)
Alanine aminotransferase U/L 56.9±69
Aspartate aminotransferase U/L 39.8±34
Gamma-glutamyltransferase U/L 25.5±19.6
Alpha-fetoprotein ng/mL 4.5±7.5
Median of histology activity index 
(range)
5 (1-16)
Median of fibrosis (range) 2 (0-5)
Data were shown as mean±standard deviation and median (Interquartile range)
HBV: Hepatitis B virus
Table 2. Demographic characteristics and laboratory findings of normal or minimally affected liver and chronic hepatitis groups
Characteristics





Gender (male) 37 (50.0) 103 (64.4) 0.037
Age (years) 37±11.4 43.5±10.8 <0.001
HBV-DNA IU/mL 25.9x103 (7.7x103-134.6x103) 45.8x103 (7,7x103-1696,2x103) 0.161
ALT U/L 27.5 (20-39.5) 45 (23-83) <0.001
AST U/L 24 (22-33) 34 (24-49) <0.001
GGT U/L 17 (12-23) 23 (15-32) <0.001
AFP ng/mL 2.5 (1.7-3.4) 3.2 (2.35-4,8) 0.002
HAI 3 (2-4) 6 (5-8) <0.001
HAI (>4) 0 122 (76.3) <0.001
Fibrozis 1 (0-1) 2 (2-3) <0.001
Fibrozis (>1) 0 123 (76.9) <0.001
HBV-DNA 
Level
>20.000 44 (59.4) 100 (42.7) 0.65
>100.000 IU/mL 20 (27) 65 (40.6) 0.04
>1.000.000 IU/mL 9 (12.2) 46 (28.8) 0.005
Data were shown as mean±standard deviation, median (Interquartile range) and n (%)
HBV: Hepatitis B virus, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, GGT: Gamma-glutamyl transpeptidase, AFP: Alpha fetoprotein, HAİ: Histological 
activity index
Table 3. Results of receiver operating characteristic analysis for various biomarkers in predicting chronic hepatitis compared to normal or minimally 
affected liver
HBV-DNA ALT AST GGT AFP
AUC 0.557 0.658 0.694 0.649 0.646
CI 95% of AUC 0.491-0.622 0.594-0.719 0.631-0.753 0.582-0.712 0.570-0.717
p 0.141 <0.001 <0.001 <0.001 0.002
Cut-off point >789.3x103 >45 >29 >25 >2.5
Sensitivity 32.5 49.38 63.52 42.38 71.90
Specificity 87.84 83.78 67.57 82.86 50.98
PPV 85.2 86.8 80.8 84.2 77.7
NPV 37.6 43.4 46.3 40.0 43.3
HBV: Hepatitis B virus, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, GGT: Gamma-glutamyl transpeptidase, AFP: Alpha-fetoprotein, AUC: Area Under 
the ROC Curve, CI: Confidence interval, PPV: Positive predictive value, NPV: Negative predictive value
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ROC curve analysis was performed and the optimal cut-off ALT, 
AST, GGT, and AFP values were determined for identifying CH. 
The AUC values were derived as 0.658 (95% confidence interval 
(CI)=0.594 to 0.719) for ALT, 0.694 (95% CI=0.631 to 0.753) for 
AST, and 0.649 (95% CI=0.582 to 0.712) for GGT. AST levels higher 
than 29 U/L have 63.52% sensitivity and 67.57% specifity for CH. 
Similarly AFP levels higher than 2.5 U/L have 71.9% sensitivity and 
50.98% specifity for CH. The results of ROC curve analysis are 
shown in Table 3.
Multivariate logistic regression analysis was performed in order 
to identify factors associated with CH. Age, AST, and AFP were 
the significant independent risk factors for CH. The results of 
multivariate logistic regression analysis are shown in Table 4.
Discussion
In this study, we investigated associations between CH 
and some demographic and laboratory parameters such as age, 
gender, ALT, AST, GGT, AFP, and HBV-DNA in HBeAg-negative CHB 
patients. According to our results, age, gender, ALT, AST GGT, AFP, 
and HBV-DNA levels >100.000 IU/mL were associated with CH in 
univariate analysis. However in multivariate analysis only age, AST 
and AFP levels were associated with CH.
AST and ALT are normally contained in liver cells. In liver 
diseases such as in viral hepatitis, the liver cells spill the enzymes 
into the blood, raising the enzyme levels in the blood and signaling 
that the liver was damaged (8). In a study which was investigated 
relationship between histopathological features of liver and serum 
transaminase levels, AST was found a better laboratory screening 
test for finding the severity of liver injury than ALT in HBeAg-
negative CHB patients (9). Similarly, our results showed that AST 
levels are more useful in showing liver damage than ALT. The 
normal limits of AST have been investigated in very few studies. 
It is recommended to adopt 40 U/L as the upper limit of AST 
(10). This value may be different in cases who have stage 3 or 
higher fibrosis, which was very low in our study. Inthis study the 
cut off level of AST was found to be 29 U/L. This suggests that 
normal AST levels in our country should be determined by large 
epidemiological studies.
Our results indicate that high levels of AFP was the second 
independent laboratory parameter related with CH. AFP is a 
glycoprotein that normally produced in early pregnancy by the 
fetal yolk sac, liver and gastrointestinal tract (11). In adults, AFP 
levels are elevated in acute or chronic viral hepatitis, chronic 
liver disease, non-alcoholic fatty liver disease, and especially in 
gonadal tumors and hepatocellular carcinoma (12). Also, it was 
shown that elevated serum AFP levels are associated with hepatic 
steatosis and ≥stage 2 fibrosis (13). Elevated serum AFP levels in 
these hepatic diseases are depend on the ongoing inflammation, 
altered hepatocyte-hepatocyte interaction or the loss of normal 
achitectural arrangements (14). According to our results, the cut off 
point of AFP is 2.5 ng/mL. However, this cut-off value is under the 
ULN value for AFP. This situtation might be related with observer 
difference in our pathologists.
Age was another parameter found as a prognostic factor 
for CH. The relationship between age and fibrosis was found in 
multiple studies. the average age was found lower in patients with 
mild fibrosis than in those with severe fibrosis (15). In another 
study, positive correlation was found between age and fibrosis, too 
(16). It should be noted that the duration of the disease may also be 
related to the fibrosis score. Our results revealed that the average 
age was higher in HBeAg-negative CHB patients with CH than in 
those with NL (43.5 years vs 37 years). Interestingly, according to 
our results, HBV-DNA level does not predict the necroinflammation 
and fibrosis. This finding has also been mentioned in other studies. 
Lu et al. (17) and Aktug Demir et al. (16) reported no correlation 
between the viral load, inflammatory activity, and the fibrosis score. 
As the risk of CH increases with age, patients should be followed 
up very closely after the age of 40 years and liver biopsy should be 
considered even if HBV-DNA levels and other liver tests such as 
Table 4. A multivariate logistic regression model of biomarkers and other covariates associated with chronic hepatitis
Independent variables β SE of β p OR 95% CI for OR
ALT U/L 0.001 0.015 0.971 1.001 0.971-1.031
AST U/L 0.072 0.034 0.034 1.074 1.005-1.148
GGT U/L 0.004 0.016 0.785 1.004 0.974-1.036
AFP ng/mL 0.167 0.083 0.045 1.182 1.004-1.392
Age (years) 0.056 0.020 0.005 1.058 1.017-1.099
Gender (male) 0.453 0.434 0.296 1.574 0.673-3.681
β: Regression coefficient, SE: Standard error, OR: Odds Ratio, CI: Confidence interval, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, GGT: Gamma-
glutamyl transpeptidase, AFP: Alpha-fetoprotein
Figure 1. ROC analysis of laboratory results
ROC: Receiver operating characteristic, AST: Aspartate aminotransferase, ALT: 
Alanine aminotransferase, GGT: Gamma-glutamyl transpeptidase, AFP: Alpha-
fetoprotein
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ALT are not too high. This is also important in determining the age 
at which treatment begins. Patients more than 40 years old should 
be evaluate for treatment be carefully because this age is critical 
for fibrozis.
Study Limitations
Before any conclusion we should declare our limitations. 
One of our limitation is that, we could not evaluate the effect of 
platelet results for fibrosis. Our other limitation is that, we did not 
investigate the pathologist observation difference. İf we did it, we 
could been say more accurate results.
Conclusion
As a result, age, high AST anf AFP levels are associated with 
hepatic necroinflammation in HBeAg-negative CHB. Specialist 
doctors who follow up these patients should evaluate these 
parameters more carefully.
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